These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways to help people lose weight, gain control over their blood sugar levels, and improve their heart health, a new study published in the journal Cureus says.

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.

According to a recent poll, over a quarter of Americans plan to turn to GLP-1 medications—like Ozempic—to reach their weight loss goals in the new year. And most of them happen to be Gen Z. Researchers with Tebra surveyed 1,